State of art on the mechanisms of laparoscopic sleeve gastrectomy in treating type 2 diabetes mellitus  

作　　者：Fa-Shun Liu Song Wang Xian-Shan Guo Zhen-Xiong Ye Hong-Ya Zhang Zhen Li 

机构地区：[1]Department of General Surgery,Yangpu Hospital,Tongji University School of Medicine,Shanghai 200090,China [2]Department of Endocrinology,Xinxiang Central Hospital,Xinxiang 453000,Henan Province,China [3]Central Laboratory,Yangpu District Control and Prevention Center,Shanghai 200090,China

出　　处：《World Journal of Diabetes》2023年第6期632-655,共24页世界糖尿病杂志（英文版）（电子版）

摘　　要：Obesity and type-2 diabetes mellitus(T2DM)are metabolic disorders.Obesity increases the risk of T2DM,and as obesity is becoming increasingly common,more individuals suffer from T2DM,which poses a considerable burden on health systems.Traditionally,pharmaceutical therapy together with lifestyle changes is used to treat obesity and T2DM to decrease the incidence of comorbidities and allcause mortality and to increase life expectancy.Bariatric surgery is increasingly replacing other forms of treatment of morbid obesity,especially in patients with refractory obesity,owing to its many benefits including good long-term outcomes and almost no weight regain.The bariatric surgery options have markedly changed recently,and laparoscopic sleeve gastrectomy(LSG)is gradually gaining popularity.LSG has become an effective and safe treatment for type-2 diabetes and morbid obesity,with a high cost-benefit ratio.Here,we review the mechanism associated with LSG treatment of T2DM,and we discuss clinical studies and animal experiments with regard to gastrointestinal hormones,gut microbiota,bile acids,and adipokines to clarify current treatment modalities for patients with obesity and T2DM.

关 键 词：OBESITY Type-2 diabetes mellitus Laparoscopic sleeve gastrectomy Gastrointestinal hormones ADIPOKINES Gut microbiota Bile acids 

分 类 号：R656.61[医药卫生—外科学] R587.1[医药卫生—临床医学]